Introduction: The Unsolved Challenge of Myocardial Reperfusion Injury
Myocardial ischemia/reperfusion (I/R) injury remains a significant clinical paradox in modern cardiology. While the swift restoration of blood flow—reperfusion—is the standard of care for acute myocardial infarction, the sudden influx of oxygen and nutrients paradoxically triggers a second wave of tissue damage. This injury often leads to heart failure, arrhythmias, and diminished long-term prognosis for patients with ischemic heart disease. Despite decades of research into necrosis and apoptosis, therapeutic interventions to specifically mitigate I/R injury are severely limited. Recent evidence has pointed toward ferroptosis, a unique form of iron-dependent regulated cell death, as a major driver of cardiomyocyte loss during I/R. However, the precise molecular switches that govern ferroptotic signaling in the heart have remained elusive until now.
Highlights
Research recently published in Circulation identifies TRIM28 (tripartite motif-containing 28) as a critical E3 ubiquitin ligase that suppresses myocardial ferroptosis. The study reveals that TRIM28 targets IRP2 (iron regulatory protein 2) for degradation, thereby limiting cellular iron uptake. Key findings include:
- TRIM28 expression is significantly downregulated in both animal models of I/R injury and in heart samples from patients with ischemic heart disease.
- Cardiomyocyte-specific overexpression of TRIM28 confers robust protection against I/R-induced cardiac damage and ferroptosis.
- Mechanistically, TRIM28 promotes the K48-linked ubiquitination of IRP2 at the K877 site, leading to its degradation and the subsequent downregulation of Transferrin Receptor 1 (TFR1).
- The regulatory protein p55γ acts as an upstream activator of TRIM28, and the anti-anginal drug perhexiline can pharmacologically harness this pathway to protect the heart.
Disease Burden and the Role of Ferroptosis
Ischemic heart disease is the leading cause of mortality worldwide. In the context of I/R injury, the heart is subjected to intense oxidative stress. This environment facilitates the accumulation of lipid peroxides, which, in the presence of labile iron, triggers ferroptosis. Unlike apoptosis, which is mediated by caspases, ferroptosis is characterized by the loss of glutathione peroxidase 4 (GPX4) activity and the massive accumulation of iron-dependent lipid reactive oxygen species (ROS). Because the heart is a highly metabolic organ with high mitochondrial density, it is particularly susceptible to these iron-mediated oxidative insults. Understanding how the heart regulates its internal iron homeostasis is therefore paramount to developing neuro-protective and cardio-protective strategies.
Study Design: A Multidisciplinary Approach
The research team employed a comprehensive, translational study design to investigate the role of TRIM28. The methodology integrated transcriptomic analysis, genetic mouse models, and human clinical samples. To screen for candidates, the researchers analyzed transcriptomic data from patients with heart failure and cardiomyocytes undergoing ferroptosis. This led to the identification of TRIM28 as a significantly downregulated factor.
In vivo experiments utilized adeno-associated virus serotype 9 (AAV9) for cardiomyocyte-specific overexpression of TRIM28 in mice. Conversely, tamoxifen-inducible cardiomyocyte-specific TRIM28 knockout mice were generated to study the effects of TRIM28 deficiency. The mechanistic aspects were explored through RNA sequencing, co-immunoprecipitation (Co-IP) coupled with mass spectrometry, and ubiquitinome profiling. Finally, the researchers used the Connectivity Map (CMap) database to identify perhexiline as a potential pharmacological activator of the TRIM28 pathway.
Key Findings: The TRIM28-IRP2-TFR1 Axis
The study’s results provide a clear mechanistic link between protein degradation and iron homeostasis. In cardiomyocytes subjected to hypoxia/reoxygenation (H/R) and in mouse hearts subjected to I/R, TRIM28 protein levels were found to be markedly reduced. When TRIM28 was overexpressed, the investigators observed a significant reduction in myocardial infarct size, improved cardiac function (as measured by echocardiography), and decreased markers of ferroptosis, such as malondialdehyde (MDA) and iron accumulation.
Conversely, the deletion of TRIM28 in cardiomyocytes exacerbated the injury, leading to larger infarcts and more severe iron-dependent lipid peroxidation. The team discovered that TRIM28 functions as an E3 ubiquitin ligase that specifically binds to IRP2. IRP2 is a master regulator of iron metabolism; when stable, it increases the expression of TFR1, which facilitates the uptake of iron into the cell. TRIM28 was found to promote K48-linked ubiquitination of IRP2 at the K877 residue. This ubiquitination marks IRP2 for proteasomal degradation. By keeping IRP2 levels low, TRIM28 prevents the overexpression of TFR1, thereby limiting the intracellular iron pool available to catalyze ferroptosis.
The Upstream Regulator: p55γ
The study further identified p55γ, a regulatory subunit of PI3K, as a positive regulator of TRIM28. The data showed that p55γ interacts with TRIM28, stabilizing it and enhancing its E3 ligase activity against IRP2. In clinical samples from patients with ischemic heart disease, the researchers observed a simultaneous decrease in p55γ and TRIM28, which correlated with an increase in IRP2 and TFR1. This suggests that the p55γ-TRIM28 axis is a naturally occurring defense mechanism that becomes compromised during chronic or acute cardiac stress.
Pharmacological Intervention: Perhexiline
A particularly exciting aspect of this research is the identification of perhexiline as a therapeutic agent. Perhexiline, historically used as an anti-anginal medication that shifts myocardial metabolism from fatty acid oxidation to glucose utilization, was found to upregulate both p55γ and TRIM28. In experimental models, perhexiline treatment successfully mitigated I/R-induced myocardial ferroptosis and improved cardiac recovery, mimicking the effects of TRIM28 overexpression. This suggests a potential path for drug repurposing in the setting of acute myocardial infarction.
Expert Commentary: Mechanistic Insights and Clinical Implications
This study provides a sophisticated explanation for why iron homeostasis fails during myocardial reperfusion. The identification of the TRIM28-IRP2-TFR1 axis fills a significant gap in our understanding of cardiac iron regulation. While previous studies have focused on iron export (via ferroportin) or storage (via ferritin), this research highlights the critical importance of regulated iron uptake and the role of the ubiquitin-proteasome system in managing ferroptotic triggers.
However, several considerations remain. While the AAV9 and knockout mouse data are compelling, the transition from mouse models to human clinical application is always complex. The timing of perhexiline administration—whether it must be given as a pretreatment or can be effective if administered at the time of reperfusion—is a critical question for emergency cardiology. Additionally, while TRIM28 is primarily known as a transcriptional corepressor, this study emphasizes its role as an E3 ligase in the cytoplasm, suggesting that its subcellular localization may be a key factor in its cardio-protective function.
Conclusion
The discovery of TRIM28 as an E3 ubiquitin ligase for IRP2 marks a significant milestone in myocardial ischemia research. By demonstrating that TRIM28 suppresses ferroptosis by controlling the IRP2-TFR1 signaling pathway, the researchers have identified a high-value therapeutic target. Whether through genetic modulation or pharmacological activation via agents like perhexiline, enhancing the TRIM28 pathway represents a promising strategy to protect the heart from the devastating effects of ischemia/reperfusion injury. Future clinical trials will be essential to determine if targeting this pathway can improve survival and quality of life for patients undergoing reperfusion therapy.
References
1. Zhu K, Guo J, Liu Y, et al. TRIM28 Is an E3 Ligase of IRP2 Suppressing Ischemia/Reperfusion-Induced Myocardial Ferroptosis. Circulation. 2026. PMID: 41797698.
2. Dixon SJ, Lemberg KM, Lamprecht MR, et al. Ferroptosis: an iron-dependent form of nonapoptotic cell death. Cell. 2012;149(5):1060-1072.
3. Fang X, Wang H, Han D, et al. Ferroptosis as a target for protection against cardiomyopathy. Proceedings of the National Academy of Sciences. 2019;116(7):2672-2680.
4. Baba Y, Higa JK, Shimada BK, et al. Protective role of the E3 ubiquitin ligase TRIM21 in myocardial ischemia-reperfusion injury. FEBS Open Bio. 2020;10(7):1314-1323.